hrs4r
 I want to donate

BERNAT QUERALT MERINO

Firma
BERNAT QUERALT-MERINO
Position
Investigador/a Pre-doctoral – R1
Predoctoral Researchers – R1

Publicacions

Dámaso E, Canet-Hermida J, Vargas-Parra G, Velasco À, Marín F, Darder E, Del Valle J, Fernández A, Izquierdo À, Mateu G, Oliveras G, Escribano C, Piñol V, Uchima HI, Soto JL, Hitchins M, Farrés R, Lázaro C, Queralt B, Brunet J, Capellá G, Pineda M

Highly sensitive MLH1 methylation analysis in blood identifies a cancer patient with low-level mosaic MLH1 epimutation.

CLINICAL EPIGENETICS, 2019, 11, 171-171 dx.doi.org/10.1186/s13148-019-0762-6

Cuyàs E, Queralt B, Martin-Castillo B, Bosch-Barrera J, Menendez JA

EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells.

ONCOLOGY REPORTS, 2017, 38, 263-270 dx.doi.org/10.3892/or.2017.5682

Bosch-Barrera J, Queralt B, Menendez JA

Targeting STAT3 with silibinin to improve cancer therapeutics.

CANCER TREATMENT REVIEWS, 2017, 58, 61-69 dx.doi.org/10.1016/j.ctrv.2017.06.003

Puig-Costa M, Codina-Cazador A, Cortés-Pastoret E, Oliveras-Ferraros C, Cufí S, Flaquer S, Llopis-Puigmarti F, Pujol-Amado E, Corominas-Faja B, Cuyàs E, Ortiz R, Lopez-Bonet E, Queralt B, Guardeño R, Martin-Castillo B, Roig J, Joven J, Menendez JA

Discovery and validation of an INflammatory PROtein-driven GAstric cancer Signature (INPROGAS) using antibody microarray-based oncoproteomics.

Oncotarget, 2014, 5, 1942-1954 dx.doi.org/10.18632/oncotarget.1879

Vera R, Gomez Dorronsoro M, Lopez-Ben S, Viudez A, Queralt B, Hernandez I, Ortiz-Duran MR, Zazpe C, Soriano J, Amat I, Herrera Cabezón J, Diaz E, Codina-Barreras A, Hernandez-Yagüe X, Quera A, Figueras J

Retrospective analysis of pathological response in colorectal cancer liver metastases following treatment with bevacizumab.

CLINICAL & TRANSLATIONAL ONCOLOGY, 2014, 16, 739-745 dx.doi.org/10.1007/s12094-013-1142-x

Oliveras-Ferraros C, Massaguer Vall-Llovera A, Vazquez-Martin A, Salip DC, Queralt B, Cufí S, Martin-Castillo B, Bosch-Barrera J, Brunet J, De Llorens R, Menendez JA

Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment.

ONCOLOGY REPORTS, 2012, 27, 1887-1892 dx.doi.org/10.3892/or.2012.1732

Oliveras-Ferraros C, Massaguer Vall-Llovera A, Salip DC, Vazquez-Martin A, Cufí S, Queralt B, Martin-Castillo B, Brunet J, de Llorens R, Menendez JA

Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells.

INVESTIGATIONAL NEW DRUGS, 2012, 30, 846-852 dx.doi.org/10.1007/s10637-010-9612-2

Oliveras-Ferraros C, Vazquez-Martin A, Queralt B, Adrados M, Ortiz R, Cufí S, Hernández-Yagüe X, Guardeño R, Báez L, Martin-Castillo B, Pérez-Martínez MC, Lopez-Bonet E, De Llorens R, Bernadó L, Brunet J, Menendez JA

Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models.

INTERNATIONAL JOURNAL OF ONCOLOGY, 2011, 39, 1455-1479 dx.doi.org/10.3892/ijo.2011.1155

Oliveras-Ferraros C, Vazquez-Martin A, Cufí S, Queralt B, Báez L, Guardeño R, Hernández-Yagüe X, Martin-Castillo B, Brunet J, Menendez JA

Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild-type tumor cells.

JOURNAL OF CELLULAR BIOCHEMISTRY, 2011, 112, 10-29 dx.doi.org/10.1002/jcb.22952

Formulari de contacte

About IDIBGI!

menu